Saturday 17 October 2026
Export INKT’s income statement to Excel — free account
MiNK Therapeutics, Inc.
INKT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 41.5% and free cash flow fell 32.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
9.41
0.53
−5.33%
Follow INKT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
1.08 | 1.06 | 1.38 | 1.23 |
Net Debt/EBITDA |
4.55 | 5.01 | 3.35 | 2.77 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.33 | 0.80 | 0.63 | 0.67 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.21) | (0.49) | (0.36) | (0.41) | |
Cash per Share |
3.21 | 3.13 | 1.99 | 1.75 | |
Shareholders Equity per Share |
(3.04) | (3.33) | (2.64) | (2.79) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.04) | (3.33) | (2.64) | (2.79) | |
Free Cash Flow |
(0.94) | (2.07) | (1.73) | (2.08) | |
Working Capital |
1.10 | 0.82 | 2.74 | 1.73 | |
Net Current Asset Value |
(13.94) | (14.62) | (13.04) | (14.35) | |
| Other line items | |||||
Quick Ratio |
1.06 | 1.03 | 1.31 | 1.16 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.49) | (0.36) | (0.41) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
3.03 | 3.08 | 3.03 | 3.62 | |
Average Assets |
11.17 | 9.98 | 7.32 | 6.05 | |
Average Common Equity |
(15.53) | (16.91) | (17.24) | (19.61) |
Columns are period end dates